Holen Sie sich die Stockscreener-App
7.76
0.13%
0.010
Handel nachbörslich:
7.76
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
Cullinan deals $712M to test Genrix bispecific TCE in autoimmune - BioWorld MedTech
Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $30.00 - Defense World
Cullinan Management Holds Annual Stockholders Meeting - TipRanks
Another BiTE in autoimmune: Cullinan deals $712M for Genrix asset - BioWorld MedTech
California State Teachers Retirement System Lowers Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Now Covered by Analysts at Stifel Nicolaus - Defense World
Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating a - GuruFocus
Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating and $22 Price Target | CGEM Stock News - GuruFocus
Stifel Recommends Buy Rating for Cullinan Therapeutics (CGEM) | CGEM Stock News - GuruFocus
Two Sigma Investments LP Has $514,000 Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Squarepoint Ops LLC Sells 11,673 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Two Sigma Advisers LP Grows Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics Licenses Rights to Velinotamig from Genrix Bio - Contract Pharma
Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix - MENAFN.com
Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix By Stocktwits - Investing.com India
Transcript : Cullinan Therapeutics, Inc.Special Call - MarketScreener
Cullinan expands autoimmune focus with new T cell engager license By Investing.com - Investing.com South Africa
Cullinan (CGEM) Secures Global Rights for Velinotamig from Genri - GuruFocus
Cullinan Therapeutics (CGEM) Secures Exclusive License for Velin - GuruFocus
Cullinan expands autoimmune focus with new T cell engager license - Investing.com Australia
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical - GuruFocus
Cullinan Therapeutics (CGEM) Secures Exclusive License for Velinotamig Development | CGEM Stock News - GuruFocus
Cullinan Management Enters Global License Agreement with Genrix - TipRanks
Cullinan in pact for multiple myeloma drug (CGEM:NASDAQ) - Seeking Alpha
Cullinan Therapeutics Licenses Rights to Velinotamig - marketscreener.com
Cullinan Therapeutics Licenses Rights to Velinotamig, a - GlobeNewswire
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific ... - Eagle-Tribune
Bank of America Corp DE Cuts Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by Nuveen Asset Management LLC - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Significant Decline in Short Interest - Defense World
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILI - GuruFocus
Cullinan Therapeutics IncTaiho Oncology And Cullinan Therapeutics Publish Positive Rezilient1 Trial Results - MarketScreener
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology - PR Newswire
ProShare Advisors LLC Acquires 4,124 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics to Host Analyst and Investor Event at - GlobeNewswire
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 - GuruFocus
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference | CGEM Stock News - GuruFocus
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference - Yahoo Finance
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by D. E. Shaw & Co. Inc. - Defense World
Ameriprise Financial Inc. Raises Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics (CGEM) Reveals Promising Phase 2b Results - GuruFocus
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology - GuruFocus
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology Announce Positive Results from REZILIENT1 Trial of Zipalertinib in Advanced Lung Cancer Patients - Nasdaq
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025 - GlobeNewswire
Northern Trust Corp Raises Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
115,000 Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Acquired by BNP Paribas Financial Markets - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stake Boosted by Price T Rowe Associates Inc. MD - Defense World
Cullinan Therapeutics (CGEM) Projected to Announce Quarterly Earnings on Wednesday - Defense World
Cullinan Therapeutics (CGEM): UBS Lowers Price Target but Mainta - GuruFocus
Cullinan Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
1.11%
1.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):